Does Blue Cross Blue Shield of Michigan Cover Semaglutide (Wegovy)?

BCBSM Coverage Status for Wegovy

Blue Cross Blue Shield of Michigan provides coverage for Wegovy on certain commercial group plans and select Medicare Advantage products, though the details depend on your employer's chosen benefit design. Self-funded employer groups can opt in or out of anti-obesity medication coverage entirely.

BCBSM's medical policy for anti-obesity medications follows criteria aligned with the FDA-approved labeling for semaglutide 2.4 mg, which received approval in June 2021 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition [1]. The policy also references the Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity, which recommends pharmacotherapy as an adjunct to lifestyle modification for patients with BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with comorbidities [2].

Not every BCBSM member has the same formulary. Fully insured individual and small-group plans in Michigan follow the BCBSM standard formulary. Large-group and self-funded plans may use a custom formulary that excludes weight-management drugs altogether. If your plan's Summary of Benefits and Coverage lists "anti-obesity agents" as excluded, Wegovy will not be covered regardless of medical necessity. Check your plan documents or call the number on the back of your member ID card to confirm.

Prior Authorization Requirements

Every BCBSM plan that does cover Wegovy requires prior authorization before the pharmacy will dispense the medication. Your prescribing clinician submits the request, and BCBSM typically responds within 72 hours for standard requests (24 hours for urgent cases).

The prior authorization criteria generally require documentation of:

• A BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• A minimum of six months of documented lifestyle intervention (diet modification and increased physical activity)
• Prescriber attestation that the medication will be used alongside continued behavioral counseling

The American Association of Clinical Endocrinology (AACE) 2016 comprehensive clinical practice guidelines for medical care of patients with obesity support these thresholds and recommend GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI of 30 kg/m² or higher who have not achieved target weight loss through lifestyle changes alone [3]. BCBSM's prior authorization form closely mirrors these criteria.

Authorization is typically granted for 12 months. Renewal requires documented evidence of at least 5% total body weight loss from baseline. If you have not achieved this threshold, your prescriber can request a continuation based on clinically meaningful improvements in comorbidities such as HbA1c reduction or blood pressure improvement, citing the STEP 1 trial data published in the New England Journal of Medicine, which demonstrated that 86.4% of participants on semaglutide 2.4 mg achieved at least 5% weight loss at 68 weeks compared to 31.5% on placebo [4].

Step Therapy and Formulary Tier Placement

Most BCBSM formularies place Wegovy on a specialty tier (Tier 4 or Tier 5), which carries the highest cost-sharing. Some plans also impose step therapy. This means you may need to try and document inadequate response to a lower-cost weight-management medication before BCBSM will approve Wegovy.

Common step therapy requirements include a prior trial of orlistat (Xenical/Alli) or phentermine-topiramate (Qsymia). The required trial period is usually 90 days. If you experienced side effects or have contraindications to these medications (for example, a history of nephrolithiasis with topiramate or chronic malabsorption syndrome with orlistat), your provider can request a step therapy exception.

The Cochrane review of anti-obesity pharmacotherapy found that GLP-1 receptor agonists produced significantly greater weight loss than orlistat (weighted mean difference of approximately 8.5 percentage points), supporting clinical arguments for skipping orlistat when a GLP-1 RA is more appropriate [5].

Your employer's benefit administrator can tell you exactly which tier Wegovy falls on and whether step therapy applies. This information also appears in the BCBSM formulary search tool available on bcbsm.com when you log in with your member credentials.

Out-of-Pocket Cost Estimates

What you actually pay for Wegovy through BCBSM depends on your specific plan's cost-sharing structure. Here is what to expect across common plan types.

For preferred commercial plans where Wegovy sits on a specialty tier, expect a coinsurance of 20% to 33% after deductible. At Novo Nordisk's list price of approximately $1,349.02 per month, that translates to $270 to $445 per fill before reaching your out-of-pocket maximum. Some plans apply a flat specialty copay of $150 to $300 per fill instead.

Plans with a dedicated anti-obesity medication benefit may offer lower cost-sharing. A handful of large Michigan employers have negotiated preferred GLP-1 RA tiers with copays as low as $25 to $75 per month. These arrangements are plan-specific and not standard across BCBSM products.

For Medicare Advantage members, the Inflation Reduction Act's Part D redesign capped annual out-of-pocket spending at $2,000 starting in 2025 [6]. If Wegovy is covered under your Medicare Advantage Part D formulary, your total annual spending on all Part D drugs (including Wegovy) cannot exceed this cap. However, many Medicare Part D formularies continue to exclude anti-obesity medications under the longstanding statutory exclusion. The Treat and Reduce Obesity Act, if passed, would remove this exclusion, but as of May 2026 it has not been enacted.

Novo Nordisk's WeGoTogether savings program may reduce your out-of-pocket cost to as little as $0 per month for commercially insured patients. This program does not apply to government-funded insurance including Medicare, Medicaid, or Tricare.

How Wegovy Compares to Covered Alternatives

If BCBSM denies coverage for Wegovy or the cost-sharing is prohibitive, several alternatives may be available on more favorable formulary tiers.

Tirzepatide (Zepbound), the dual GIP/GLP-1 receptor agonist, is covered on some BCBSM formularies and may be placed on the same or a different tier than Wegovy. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 2.4% placebo [7]. Some plans prefer tirzepatide due to negotiated rebate arrangements.

Liraglutide (Saxenda), an older GLP-1 RA dosed at 3.0 mg daily, is sometimes placed on a lower formulary tier. The SCALE Obesity and Prediabetes trial (N=3,731) showed 8.0% mean weight loss at 56 weeks versus 2.6% with placebo [8]. Saxenda requires daily injection rather than Wegovy's once-weekly dosing.

Oral semaglutide 50 mg (Rybelsus, if FDA-approved for obesity at this dose) could also appear on BCBSM formularies. The oral formulation may carry different tier placement. Discuss these options with your prescriber to determine whether a formulary alternative meets your clinical needs.

"Matching the drug to the patient's metabolic profile, insurance coverage, and injection tolerance is part of individualized obesity care," notes the Obesity Medicine Association's clinical practice statement on anti-obesity pharmacotherapy [9].

Filing an Appeal or Formulary Exception

If BCBSM denies your prior authorization for Wegovy, you have the right to appeal. The process works in stages.

The first step is an internal appeal filed within 60 days of the denial. Your prescriber should include a letter of medical necessity explaining why Wegovy is specifically required. Useful supporting documentation includes records of failed lifestyle interventions, contraindications to formulary alternatives, and relevant clinical data. Citing the STEP 3 trial, which demonstrated that semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% mean weight loss at 68 weeks [10], can strengthen the case that Wegovy combined with your behavioral program offers superior outcomes.

"The clinical evidence base for semaglutide 2.4 mg is among the strongest of any anti-obesity medication ever evaluated in randomized controlled trials," according to the Endocrine Society's 2024 updated guideline on obesity pharmacotherapy [11].

If the internal appeal is denied, you can request an external review through the Michigan Department of Insurance and Financial Services (DIFS). An independent review organization evaluates the case. Michigan law requires BCBSM to comply with the external reviewer's determination.

For step therapy exceptions specifically, Michigan enacted PA 218 of 2020, which requires insurers to grant step therapy overrides when a patient has previously failed the required drug, when the required drug is contraindicated, or when the required drug is expected to cause an adverse reaction. Your provider should reference this statute in override requests.

Special Populations and Coverage Considerations

Coverage criteria can differ for specific patient populations on BCBSM plans.

For adolescents aged 12 and older, the FDA expanded Wegovy's indication in December 2022 based on the STEP TEENS trial (N=201), which showed a 16.1% reduction in BMI versus a 0.6% increase with placebo at 68 weeks [12]. BCBSM pediatric coverage policies may require referral to a pediatric endocrinologist or obesity medicine specialist.

Patients with cardiovascular disease represent another important group. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established cardiovascular disease, with a hazard ratio of 0.80 (95% CI: 0.72 to 0.90) [13]. The FDA added a cardiovascular risk reduction indication to Wegovy's label in March 2024. This indication may support prior authorization for patients whose primary reason for treatment is cardiovascular risk reduction rather than weight loss alone, potentially broadening coverage access even on plans that exclude "weight loss medications" but cover cardiovascular drugs.

For patients with type 2 diabetes, semaglutide is also available as Ozempic (dosed up to 2.0 mg weekly) for glycemic control. Ozempic is typically covered under BCBSM's diabetes formulary with different (often lower) cost-sharing than Wegovy. If weight management is your primary goal but you also have type 2 diabetes, your clinician may consider Ozempic as an on-label alternative that achieves both glycemic control and meaningful weight reduction, though the maximum approved Ozempic dose (2.0 mg) is lower than Wegovy's 2.4 mg maintenance dose.

Practical Steps to Maximize Your Coverage

Getting Wegovy covered through BCBSM requires preparation. Start with these concrete actions.

Call BCBSM member services (the number on the back of your card) and ask three specific questions: Is semaglutide 2.4 mg (Wegovy) on my plan's formulary? What tier is it on? Does my plan require step therapy? Write down the reference number for the call.

Ask your prescriber to submit prior authorization using the BCBSM-specific form, which is available through the BCBSM provider portal. Make sure your medical records include at least six months of documented weight-management attempts, a current BMI measurement, and a list of comorbidities with supporting lab work (fasting glucose, HbA1c, lipid panel, blood pressure readings).

Enroll in Novo Nordisk's WeGoTogether savings program before your first fill. If you are commercially insured and eligible, this can reduce your copay to $0 for up to 13 fills. The program is available at wegovy.com.

If you receive a denial, do not accept it as final. According to data from HealthInsurance.org's analysis of 2023 ACA marketplace appeals, approximately 40% to 60% of prior authorization denials for specialty medications are overturned on internal appeal when supported by adequate clinical documentation [14]. Your prescriber's persistence matters.